

I-SPY 2 TRIAL -Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2

Status: Recruiting

Eligibility Criteria

Age: 18 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

- invasive breast cancer confirmed by biopsy - tumor is at least 2.5 cm in size - no prior chemotherapy for this cancer - no restrictions in activity or partially restricted with work, but able to independently care for self - willing to have another breast biopsy - not pregnant or breast feeding - consult study staff for additional requirements

Exclusion Criteria:

- other medical or mental health diagnosis that would limit compliance with study requirements

Conditions & Interventions

Conditions:

Cancer

Keywords:

Breast Cancer, Breast Tumors, I-SPY, ISPY, ISPY2

More Information

Description: To determine whether adding experimental agents to standard neoadjuvant paclitaxel (with or without trastuzumab), doxorubicin, and cyclophosphamide increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry, and to determine for each experimental agent used, the predictive probability of success in a subsequent phase 3 trial for each possible biomarker signature.

Contact(s): Douglas Yee - yeexx006@umn.edu

Principal Investigator: Douglas Yee, MD

IRB

Number: STUDY00011111

System ID: 38844

Thank you for choosing StudyFinder. Please visit <http://studyfinderstaging.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.